NCT06450210View on ClinicalTrials.gov

Safety for Home Administration of Microdose Psilocybin Use

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Psychedelic Experiences
Interventions
DRUG

psilocybin trihydrate

Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).

DRUG

Placebo

Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.

Trial Locations (1)

21224

RECRUITING

5510 Nathan Shock Drive, Baltimore

All Listed Sponsors
collaborator

Private Philanthropic Funds

OTHER

lead

Johns Hopkins University

OTHER